Targeted prostate biopsies using a technique that combines magnetic resonance imaging (MRI) with real-time 3D ultrasound may improve prostate cancer detection, according to a report in the online May/June issue of the journal Urologic Oncology.
Dynamic contrast enhanced (DCE) endorectal magnetic resonance imaging (MRI) of the pelvis may offer an effective method of assessing for local recurrence of prostate cancer (PCa) after prostatectomy, according to Texas researchers.
SAN DIEGO—Magnetic resonance imaging (MRI) using gadolinium-based contrast agents is safe in intensive care unit (ICU) patients at high risk for kidney injury, according to the results of a small retrospective study presented in poster format at the Society for Critical Care Medicine 2011 annual meeting.
CHICAGO—Time may not be as serious an issue as previously thought when it comes to image-guided percutaneous thrombectomy in the setting of clotted surgical dialysis access, according to researchers.
VIENNA—Real-time elastography has significantly better predictive accuracy for identifying prostate cancer (PCa) lesions compared with contrast-enhanced magnetic resonance imaging (MRI), researchers reported here at the 26th Annual Congress of the European Association of Urology. Biopsy studies need to confirm these results, however.
ORLANDO—Radiographic imaging studies often are used inappropriately for men with newly diagnosed prostate cancer (PCa), with certain patients undergoing unnecessary imaging and others not receiving imaging even though it is recommended, researchers concluded.
Hypofractionated image-guided radiation could delay use of systemic therapy, which can be quite toxic.
Targeted prostate biopsies using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may enable surgeons to select candidates for focal therapy of early-stage prostate cancer, according to researchers.
Magnetic resonance imaging (MRI) may be superior to computed tomography for radiographic surveillance following laparoscopic renal cryoablation of renal masses, researchers reported at the World Congress of Endourology in Chicago.
SAN FRANCISCO—For the first time, clinicians may have an imaging tool that can help distinguish clear cell renal cell carcinoma (RCC) from other kinds of renal masses.
